Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation

International Journal of Gastrointestinal Cancer

Volumn 35, Issue 1, 2005, Pages 53-60

  Kannangai, Rajesh ^a   Wang, Jianzhou ^b,c   Liu, Qiong Z ^c   Sahin, Fikret ^a   Torbenson, Michael ^a,d  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Ameripath Inc   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; p53; Survivin

Indexed keywords

APOPTOSIS INHIBITOR; MESSENGER RNA; PROTEIN P53; SURVIVIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BILE DUCT CARCINOMA; BIOACCUMULATION; CANCER RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBROLAMELLAR CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CARCINOMA; LIVER CELL CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; UNITED STATES; WILD TYPE;

EID: 16244387945     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:35:1:053     Document Type: Article

References (22)

1. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survival in human and mouse differentiation. Am J Pathol 1998;152:43-49.
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
3. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
4. Deguchi M, Shiraki K, Inoue H, et al. Expression of survivin during liver regeneration. Biochem Biophys Res Commun 2002;297:59-64.
5. Shiraki K, Nakano T, Hisatomi H. Survivin in liver. Gastroenterology 2003;124:1565-1566; author reply 1566-1567.
6. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 2002;8:3131-3136.
7. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000;31:1080-1085.
8. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 2002;95:1938-1945.
9. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
10. Grossman D, Kim PJ, Blanc-Brude OP, et al. Transgenic expression of survivin in keratinocytes counteracts UVB -induced apoptosis and cooperates with loss of p53. J Clin Invest 2001;108:991-999.
11. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-3257.
12. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53 dependent apoptotic pathway. Oncogene 2002;21:2613-2622.
13. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-6102.
14. Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002;9:1334-1342.
15. Hung CJ, Ginzinger DG, Zarnegar R, et al. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab 2003;88:3694-3699.
16. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinicohistopathologic study of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
17. Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol 2002;15:189-196.
18. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002;11:33-40.
19. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002;86:737-743.
20. Li F. Survivin study: what is the next wave? J Cell Physiol 2003;197:8-29.
21. Marwoto W, Miskad UA, Siregar NC, et al. Immunohistochemical study of P53, PCNA and AFP in hepatocellular carcinoma, a comparison between Indonesian and Japanese cases. Kobe J Med Sci 2000;46:217-229.
22. Moon WS, Tarnawski AS. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol 2003;34:1119-1126.